AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KJUL 13 min read$ICU

SeaStar Medical Holding Corp (ICU): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

SeaStar Medical Holding Corp (ICU) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. icu20260630_8k.htm false 0001831868 0001831868 2026-06-25 2026-06-25 0001831868 icu:CommonStockCustomMember 2026-06-25 2026-06-25 0001831868 icu:WarrantsEachWholeWarrantExercisableForOneShareOfCommonStockFor1150PerShareCustomMember 2026-06-25 2026-06-25 UNITED STATES SECURITIES A

Original reporting
SEC EDGAR 8-K
Published Jul 1, 2026, 8:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 1, 2026, 8:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
$ICU
Neutral
medium confidence
Mentioned
$ICU
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$ICUNeutralLow
01

Why it matters

The disclosure provides concrete compensation terms (cash amounts, vesting/payment dates, and stock-based share settlement mechanics) for two executives, which can influence expectations around future dilution and retention stability.

02

Market read

Traders may monitor for small dilution/issuance expectations tied to the scheduled vesting dates, but there is no operational or financial guidance change.

03

What to watch

If the company’s share price is volatile, the share count delivered at each vesting date (based on closing price) could change the effective dilution more than the dollar bonus amounts suggest.

Relevance 6/10Novelty 5/10Timing: Filed July 1, 2026; vesting payments scheduled July 1, 2026, Nov 1, 2026, and Mar 1, 2027.

Background

The company filed an SEC Form 8-K (Item 5.02) describing retention bonuses approved by the Compensation Committee and formalized via retention bonus program agreements.

Company-level read

Ticker impact

$ICUNeutralMedium confidence
Context

SeaStar Medical Holding approved retention bonuses for executives Eric Schlorff and Kevin Chung, with vesting/pay dates through March 1, 2027.

Expected impact

Likely limited, with any impact concentrated around vesting/payment dates rather than immediately.

Evidence & confidence

The filing discloses specific bonus amounts and vesting schedule, but it is not a financing, guidance change, or operational milestone; effects are typically incremental for microcaps.

Market effects

Sector

No direct sector read-across; this is company-specific compensation/retention disclosure.

Regional

None indicated; Nasdaq-listed filing with no macro/regional catalyst.

Global

None indicated; no international transaction or regulatory action described.

Counterpoint

What could challenge this read

The stock-based component (25% of each payment in shares) could be viewed as supportive for retention and continuity, potentially reducing execution risk despite dilution.

Key entities

  • company
    SeaStar Medical Holding Corporation

    Nasdaq-listed registrant (ICU) disclosing executive retention bonuses and vesting/payment schedule via Form 8-K.

  • executive
    Eric Schlorff

    Executive receiving a $200,000 retention bonus split into three 1/3 payments with stock-based add-on.

  • executive
    Kevin Chung

    Executive receiving a $140,000 retention bonus split into three 1/3 payments with stock-based add-on.

Read at source← All news

Related articles

OCT 7
$ICUHighAI 8/10

FDA Grants SeaStar Medical Breakthrough Device Designation for its SCD Therapy for the Treatment of Hyperinflammation in Adult Patients with Sepsis or a Septic Condition

SeaStar Medical (ICU) received FDA Breakthrough Device Designation for its SCD therapy to treat hyperinflammation in adult sepsis patients. This designation accelerates development and review. Sepsis affects 1.7M U.S. adults annually, with high mortality rates. The company plans to submit data to the FDA soon. This is the seventh such designation for the SCD therapy across various indications.

globenewswire.com2 min
OCT 1
$ICUMed

New ICD-10-PCS Codes are Now Available for the Use of SeaStar Medical’s SCD Therapy for Acute Kidney Injury (AKI)

SeaStar Medical (ICU) announced new ICD-10-PCS codes for its SCD therapy in treating acute kidney injury (AKI). The codes streamline hospital billing and expand access to QUELIMMUNE therapy. The company expects this to support broader adoption and potential future indications. QUELIMMUNE showed a 77% survival rate in clinical trials, with no dialysis required for survivors.

globenewswire.com2 min
AUG 13
$ICUMed

SeaStar Medical (ICU) Q2 2026 Earnings Call Transcript

SeaStar Medical Holding Corp (ICU) reported Q2 2026 net revenue of $615,000, up 82% year over year, and six-month net revenue of $1.1 million. Gross margin was 91%. Net loss was $3.7 million ($0.91/share). Cash was $7.0 million at June 30, 2026. QUELIMMUNE adoption reached 20 hospitals; NEUTRALIZE-AKI enrolled 223/339 patients.

fool.com12 min
AUG 12
$ICUMed

SeaStar Medical Reports Second Quarter 2026 Financial Results and Provides Business Updates

SeaStar Medical Holding Corp (ICU) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SeaStar Medical Reports Second Quarter 2026 Financial Results and Provides Business Updates Added 3 top-rated children ’ s hospitals to QUELIMMUNE ® pediatric acute kidney injury (AKI) customer base, increasing net revenue 82% versus second quarter 2025 Advanced enro

SEC EDGAR 8-K7 min